Biolevate

Biolevate announced €30M in Series A financing on September 22, 2026. Biolevate raised a €30 million Series A co-led by RAISE France and Orange Ventures to expand evidence-grade automation for regulated life sciences operations.

Round details

The financing includes backing from RAISE France, Orange Ventures, MSD Global Health Innovation Fund, EQT Ventures. The company did not publish a valuation with the announcement.

• Round: Series A
• Capital announced: €30M
• Headquarters: Paris, France

How the company plans to use the capital

Biolevate said the capital will support international expansion, deeper product capabilities, larger enterprise deployments, and a new Boston office serving the U.S. life sciences market.

Why this matters for GTM teams

The round shows growing demand for AI systems that automate regulated scientific and operational work while preserving evidence, traceability, and domain context.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Biolevate Series A announcement.